Raymond James Financial
MBIO icon

Raymond James Financial’s Mustang Bio MBIO Stock Holding History

Raymond James Financial’s Portfolio MBIO Stock Details MBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-16
Closed -$16 – 5996
2025
Q2 		$16 Buy
+16
New +$19 ﹤0.01% 6930

Other funds holding MBIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CG
CFO4Life Group Coppell, Texas $743M AUM 25.26% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Raymond James Financial's MBIO Position: Q3 2025 in Review

Raymond James Financial sold out of Mustang Bio (MBIO) in Q3 2025, closing a stake of 16 shares — an estimated $16 sold.

Raymond James Financial first reported a position in MBIO in Q2 2025 and held it in 1 quarter. The position peaked at $16 in Q2 2025. 20 funds tracked by Wall St. Rank hold MBIO as of Q3 2025.

  • Raymond James Financial reported no remaining Mustang Bio position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 16 Mustang Bio shares in Q3 2025, an estimated $16.
  • Raymond James Financial first reported a position in Mustang Bio in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Mustang Bio position peaked at $16 in Q2 2025.
  • 20 funds tracked by Wall St. Rank held Mustang Bio as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.